Jessica Vamathevan

Jessica Vamathevan
Head of EMBL-EBI Strategic Partnership Office - Directors' office

Jessica is Head of EMBL-EBI Strategic Partnership Office responsible for strategy development, planning and industry initiatives within EMBL-EBI. This is a new Office that was created to drive broader academic and industry engagement demanded by the increased utility of genomics and biological data and the growing translational applications of bioinformatics.

Prior to joining EMBL-EBI, Jessica worked for GSK as the Operations Director for Open Targets, a public-private partnership between GSK, Biogen, Takeda, EMBL-EBI and the Wellcome Sanger Institute. Jessica oversaw the management of informatics and experimental target validation projects and ensured the strategic deployment and operational translation of the initiative.

Before joining Open Targets, Jessica was a Manager in Computational Biology at GSK, working with discovery scientists in many therapeutic areas including Infectious Diseases, Respiratory, Immuno-Inflammation and Rare Diseases to deliver impactful bioinformatics projects.

She spent over six years at The Institute for Genomic Research (TIGR) in Maryland, US working on many pathogen-genome sequencing projects and a year at the Wellcome Trust Sanger Institute in human genome annotation. She also taught as a Lecturer in Molecular Evolution at University College London.

Jessica holds a PhD in Bioinformatics from University College London, an MSc in Computer Science from Johns Hopkins University and a Bachelor of Medical Science from the University of Sydney.

ORCID iD: 0000-0003-2016-9754

Tel:+ 44 (0) 1223 49 4331 / Fax:

Strategic Partnership Office

Since 1996 the Industry Programme has provided on-going and regular contact with key stakeholder groups. The programme is subscription-funded and primarily represents larger companies. The Industry Programme supports and encourages precompetitive projects by hosting regular strategy meetings and knowledge-exchange workshops. Outputs from pre-competitive projects are made publicly available, thereby sharing the benefits with interested parties in all EMBL member states. The programme serves as an interface between EMBL-EBI and the Innovative Medicines Initiative (IMI), the Pistoia Alliance and other precompetitive initiatives and encourages the involvement of industry in ELIXIR, the emerging pan-European infrastructure for biological information.



Team members

  • Gaia Cantelli
  • Edgardo Ferran
  • Matthew Hall
  • Ewan Johnstone
  • Euphemia Mutasa-Gottgens
  • Sheila Savill
  • Amonida Zadissa